Basic Information
NEBIVOLOL STELLA TABLET 5MG
TABLET
Regulatory Information
SIN16481P
May 4, 2022
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XC07AB12
Company Information
Active Ingredients
Strength: 5 mg
Detailed Information
Contraindications
**7\. Contraindications** - Hypersensitivity to the active substance or to any of the excipients. - Liver insufficiency or liver function impairment. - Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy. In addition, as with other beta-blocking agents, nebivolol is contraindicated in: - Sick sinus syndrome, including sino-atrial block. - Second and third degree heart-block (without a pacemaker). - History of bronchospasm and bronchial asthma. - Untreated phaeochromocytoma. - Metabolic acidosis. - Bradycardia (heart rate < 60 bpm prior to start therapy). - Hypotension (systolic blood pressure < 90 mmHg). - Severe peripheral circulatory disturbances.
Indication Information
**5\. Indications** Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients of ≥ 70 years.